Home >> Healthcare >> Food & Beverage >>

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015

Published: Aug-2015 | Format: PDF | Global Markets Direct | Number of pages: 129 | Code: MRS - 35125

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015’, provides an overview of the B-Cell Chronic Lymphocytic Leukemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for B-Cell Chronic Lymphocytic Leukemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the B-Cell Chronic Lymphocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the B-Cell Chronic Lymphocytic Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
B-Cell Chronic Lymphocytic Leukemia Overview 10
Therapeutics Development 11
Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Overview 11
Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis 12
B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Development by Companies 13
B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Investigation by Universities/Institutes 15
B-Cell Chronic Lymphocytic Leukemia - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
B-Cell Chronic Lymphocytic Leukemia - Products under Development by Companies 19
B-Cell Chronic Lymphocytic Leukemia - Products under Investigation by Universities/Institutes 21
B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development 22
AB Science SA 22
AbbVie Inc. 23
Advancell 24
Amgen Inc. 25
BioNovion B.V. 26
Celgene Corporation 27
Dynavax Technologies Corporation 28
Eisai Co., Ltd. 29
F. Hoffmann-La Roche Ltd. 30
Formula Pharmaceuticals, Inc. 31
iDD biotech SAS 32
Immunomedics, Inc. 33
Johnson & Johnson 34
Juno Therapeutics Inc. 35
Nippon Shinyaku Co., Ltd. 36
Noxxon Pharma AG 37
Ono Pharmaceutical Co., Ltd. 38
Regeneron Pharmaceuticals, Inc. 39
SBI Biotech Co., Ltd. 40
TheraMAB LLC 41
Vivia Biotech, S.L. 42
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Target 44
Assessment by Mechanism of Action 47
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
202-b - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AB-8779 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
acadesine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
alemtuzumab biosimilar - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
AMG-319 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
bafetinib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
BION-1301 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Cell Therapy for Hematological Malignancies - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Cell Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Cell Therapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Cell Therapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Cell Therapy to Target CD16 for CLL and NHL - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Cell Therapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Cell Therapy to Target CD19 for Cancer - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Cell Therapy to Target CD19 for Oncology - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Cell Therapy to Target CD23 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
E-7449 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
GNKS-356 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
IDD-001 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
IDD-002 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
ilorasertib - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
JNJ-64052781 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
lenalidomide - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
MAT-303 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
olaptesed pegol - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
ONO-4059 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
REGN-1979 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
SD-101 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
TAB-08 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
tocilizumab - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Vivia-009 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
B-Cell Chronic Lymphocytic Leukemia - Recent Pipeline Updates 102
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects 122
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products 124
B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones 125
Featured News & Press Releases 125
Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement 125
Dec 12, 2011: CytRx Announces Presentation Of Favorable Phase II Results With Bafetinib In Relapsed B-Cell Chronic Lymphocytic Leukemia At ASH Conference 125
Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia 126
Appendix 128
Methodology 128
Coverage 128
Secondary Research 128
Primary Research 128
Expert Panel Validation 128
Contact Us 128
Disclaimer 129

List of Tables
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2015 11
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Products under Development by Companies, H2 2015 19
Products under Development by Companies, H2 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2015 21
B-Cell Chronic Lymphocytic Leukemia - Pipeline by AB Science SA, H2 2015 22
B-Cell Chronic Lymphocytic Leukemia - Pipeline by AbbVie Inc., H2 2015 23
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Advancell, H2 2015 24
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Amgen Inc., H2 2015 25
B-Cell Chronic Lymphocytic Leukemia - Pipeline by BioNovion B.V., H2 2015 26
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Celgene Corporation, H2 2015 27
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Dynavax Technologies Corporation, H2 2015 28
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Eisai Co., Ltd., H2 2015 29
B-Cell Chronic Lymphocytic Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 30
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Formula Pharmaceuticals, Inc., H2 2015 31
B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, H2 2015 32
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics, Inc., H2 2015 33
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Johnson & Johnson, H2 2015 34
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Juno Therapeutics Inc., H2 2015 35
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015 36
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Noxxon Pharma AG, H2 2015 37
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 38
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 39
B-Cell Chronic Lymphocytic Leukemia - Pipeline by SBI Biotech Co., Ltd., H2 2015 40
B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC, H2 2015 41
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Vivia Biotech, S.L., H2 2015 42
Assessment by Monotherapy Products, H2 2015 43
Number of Products by Stage and Target, H2 2015 45
Number of Products by Stage and Mechanism of Action, H2 2015 48
Number of Products by Stage and Route of Administration, H2 2015 50
Number of Products by Stage and Molecule Type, H2 2015 52
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Recent Pipeline Updates, H2 2015 102
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H2 2015 122
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects (Contd..1), H2 2015 123
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H2 2015 124

List of Figures
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2015 11
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Products, H2 2015 18
Assessment by Monotherapy Products, H2 2015 43
Number of Products by Top 10 Targets, H2 2015 44
Number of Products by Stage and Top 10 Targets, H2 2015 44
Number of Products by Top 10 Mechanism of Actions, H2 2015 47
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 47
Number of Products by Top 10 Routes of Administration, H2 2015 49
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 49
Number of Products by Top 10 Molecule Types, H2 2015 51
Number of Products by Stage and Top 10 Molecule Types, H2 2015 51

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)2000 View Pricing